tiprankstipranks
Trending News
More News >
AlzChem Group AG (DE:ACT)
XETRA:ACT

AlzChem Group AG (ACT) AI Stock Analysis

Compare
21 Followers

Top Page

DE

AlzChem Group AG

(XETRA:ACT)

Rating:75Outperform
Price Target:
€150.00
▲(15.21%Upside)
AlzChem Group AG's overall stock score reflects its strong financial performance and positive technical indicators, balanced by a reasonable valuation. The lack of recent earnings call data and new corporate events leaves the financial and technical aspects as the primary drivers of this score.

AlzChem Group AG (ACT) vs. iShares MSCI Germany ETF (EWG)

AlzChem Group AG Business Overview & Revenue Model

Company DescriptionAlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand. It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name. In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases. Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.
How the Company Makes MoneyAlzChem Group AG generates its revenue through the production and sale of specialty chemicals. The company has diverse revenue streams, primarily derived from its key sectors: agriculture, where it supplies fertilizers and crop protection products; pharmaceuticals, providing high-purity chemicals for medical applications; metallurgy, offering additives and agents for metal processing; and electronics, supplying materials for advanced technological manufacturing. The company benefits from long-term contracts and partnerships with major industrial clients, which contribute to stable revenue flows. Additionally, its focus on innovation and development of high-value specialty products allows it to maintain competitive pricing, thereby enhancing profitability.

AlzChem Group AG Financial Statement Overview

Summary
Overall, AlzChem Group AG exhibits impressive financial health, characterized by strong revenue growth, efficient cost management, and improved profitability. The balance sheet reflects a stable financial position with manageable leverage. Cash flow metrics indicate robust cash generation, supporting sustainable growth.
Income Statement
88
Very Positive
AlzChem Group AG has demonstrated strong revenue growth, with a significant increase from 2023 to 2024. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, showcasing enhanced profitability. Both EBIT and EBITDA margins are strong, reflecting effective operational performance.
Balance Sheet
75
Positive
The company's balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. Return on equity has improved, demonstrating efficient use of equity capital. The equity ratio is stable, supporting asset financing through equity.
Cash Flow
82
Very Positive
AlzChem Group AG has shown robust growth in free cash flow, signifying improved operational efficiency. The operating cash flow to net income ratio is strong, indicating effective cash generation from operations. Free cash flow to net income ratio highlights the company's ability to convert earnings into cash flow.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
547.05M554.23M540.65M542.22M422.29M379.26M
Gross Profit
340.50M339.26M304.07M282.72M268.34M250.58M
EBIT
109.03M173.35M52.24M39.09M38.22M31.01M
EBITDA
103.04M98.44M81.75M68.06M61.89M51.39M
Net Income Common Stockholders
56.47M54.08M34.62M30.05M27.59M19.69M
Balance SheetCash, Cash Equivalents and Short-Term Investments
12.93M63.15M13.92M9.62M8.73M17.47M
Total Assets
295.48M483.83M424.68M422.86M377.67M354.30M
Total Debt
47.61M52.82M62.49M100.23M55.64M69.06M
Net Debt
34.68M-8.72M50.60M90.99M47.36M51.94M
Total Liabilities
230.72M276.36M261.12M276.91M288.10M285.64M
Stockholders Equity
62.56M205.54M161.63M144.01M87.63M66.89M
Cash FlowFree Cash Flow
72.57M62.05M52.11M-33.31M14.48M19.88M
Operating Cash Flow
121.21M105.15M72.67M-4.24M43.02M48.71M
Investing Cash Flow
-37.20M-30.99M-20.55M-28.51M-28.48M-28.83M
Financing Cash Flow
-28.70M-24.66M-49.17M33.65M-23.62M-11.73M

AlzChem Group AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price130.20
Price Trends
50DMA
112.36
Positive
100DMA
92.89
Positive
200DMA
73.09
Positive
Market Momentum
MACD
5.39
Negative
RSI
60.56
Neutral
STOCH
85.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ACT, the sentiment is Positive. The current price of 130.2 is above the 20-day moving average (MA) of 124.53, above the 50-day MA of 112.36, and above the 200-day MA of 73.09, indicating a bullish trend. The MACD of 5.39 indicates Negative momentum. The RSI at 60.56 is Neutral, neither overbought nor oversold. The STOCH value of 85.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:ACT.

AlzChem Group AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DEACT
75
Outperform
€1.32B24.3529.46%1.39%2.51%56.13%
51
Neutral
$2.02B-1.19-21.37%3.64%2.88%-30.57%
€8.81B16.5811.49%3.45%
€11.06B-6.00%
€8.90B29.813.25%6.12%
$2.53B-3.92%0.36%
$3.52B13.675.37%3.77%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:ACT
AlzChem Group AG
130.20
86.03
194.77%
GB:0MPT
Brenntag AG
60.96
-1.99
-3.16%
GB:0RBE
Covestro
60.06
8.15
15.70%
GB:0QDS
Evonik
19.18
1.66
9.47%
LNXSF
LANXESS
29.75
5.62
23.29%
WKCMF
Wacker Chemie AG
74.68
-24.55
-24.74%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.